Energenesis Biomedical Co. Ltd.
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel … Read more
Energenesis Biomedical Co. Ltd. (6657) - Total Liabilities
Latest total liabilities as of September 2025: NT$37.85 Million TWD
Based on the latest financial reports, Energenesis Biomedical Co. Ltd. (6657) has total liabilities worth NT$37.85 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Energenesis Biomedical Co. Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Energenesis Biomedical Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Energenesis Biomedical Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Energenesis Biomedical Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PT Harum Energy Tbk
F:44H
|
Germany | €1.34 Billion |
|
New Power Plasma Co.Ltd
KQ:144960
|
Korea | ₩567.46 Billion |
|
Shanthi Gears Limited
NSE:SHANTIGEAR
|
India | ₹943.00 Million |
|
Integrated Wind Solutions AS
OL:IWS
|
Norway | Nkr235.93 Million |
|
SCHMID Group N.V. Class A Ordinary Shares
NASDAQ:SHMD
|
USA | $195.08 Million |
|
LuxExperience B.V.
NYSE:LUXE
|
USA | $862.02 Million |
|
Kee Tai Properties Co Ltd
TW:2538
|
Taiwan | NT$11.91 Billion |
|
Uniplus Electronics Co Ltd
TWO:5381
|
Taiwan | NT$2.57 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Energenesis Biomedical Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 34.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Energenesis Biomedical Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Energenesis Biomedical Co. Ltd. (2019–2024)
The table below shows the annual total liabilities of Energenesis Biomedical Co. Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$41.30 Million | +68.00% |
| 2023-12-31 | NT$24.59 Million | -13.14% |
| 2022-12-31 | NT$28.31 Million | -15.34% |
| 2021-12-31 | NT$33.44 Million | +2.80% |
| 2020-12-31 | NT$32.52 Million | +19.96% |
| 2019-12-31 | NT$27.11 Million | -- |